Log in

Supernus Pharmaceuticals Stock Price, Forecast & Analysis (NASDAQ:SUPN)

$22.08
+0.25 (+1.15 %)
(As of 11/16/2019 08:00 AM ET)
Today's Range
$21.61
Now: $22.08
$22.10
50-Day Range
$19.54
MA: $25.97
$29.04
52-Week Range
$19.35
Now: $22.08
$49.25
Volume411,500 shs
Average Volume910,332 shs
Market Capitalization$1.16 billion
P/E Ratio10.77
Dividend YieldN/A
Beta1.63
Supernus Pharmaceuticals, Inc, a pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy and migraine. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNASDAQ:SUPN
CUSIP86845910
Phone301-838-2500

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$408.90 million
Cash Flow$2.48 per share
Book Value$10.62 per share

Profitability

Net Income$110.99 million

Miscellaneous

Employees448
Market Cap$1.16 billion
Next Earnings Date2/25/2020 (Estimated)
OptionableOptionable

Receive SUPN News and Ratings via Email

Sign-up to receive the latest news and ratings for SUPN and its competitors with MarketBeat's FREE daily newsletter.


Supernus Pharmaceuticals (NASDAQ:SUPN) Frequently Asked Questions

What is Supernus Pharmaceuticals' stock symbol?

Supernus Pharmaceuticals trades on the NASDAQ under the ticker symbol "SUPN."

How were Supernus Pharmaceuticals' earnings last quarter?

Supernus Pharmaceuticals Inc (NASDAQ:SUPN) posted its earnings results on Tuesday, November, 5th. The specialty pharmaceutical company reported $0.54 EPS for the quarter, missing the Thomson Reuters' consensus estimate of $0.59 by $0.05. The specialty pharmaceutical company had revenue of $102.14 million for the quarter, compared to the consensus estimate of $108.70 million. Supernus Pharmaceuticals had a return on equity of 21.02% and a net margin of 25.92%. Supernus Pharmaceuticals's quarterly revenue was down .8% compared to the same quarter last year. During the same period in the prior year, the business earned $0.52 EPS. View Supernus Pharmaceuticals' Earnings History.

When is Supernus Pharmaceuticals' next earnings date?

Supernus Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Supernus Pharmaceuticals.

What price target have analysts set for SUPN?

8 brokers have issued 1 year target prices for Supernus Pharmaceuticals' shares. Their forecasts range from $23.00 to $65.00. On average, they anticipate Supernus Pharmaceuticals' stock price to reach $46.86 in the next twelve months. This suggests a possible upside of 112.2% from the stock's current price. View Analyst Price Targets for Supernus Pharmaceuticals.

What is the consensus analysts' recommendation for Supernus Pharmaceuticals?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Supernus Pharmaceuticals in the last year. There are currently 4 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Supernus Pharmaceuticals.

What are Wall Street analysts saying about Supernus Pharmaceuticals stock?

Here are some recent quotes from research analysts about Supernus Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland. " (11/6/2019)
  • 2. Mizuho analysts commented, "Valuation and risks to price target achievement. We reiterate our Buy rating and are adjusting our price target to $18 from $3, based on the following factors: (1) adjustment to base year; (2) adjustment ot fully diluted share count; (3) accounting for the 1 for 15 reverse split; and (4) increasing our discount rate to 30% from our usual 15%, to account for increased perceived risk in developing drugs for both pancreatic cancer and AML. We note that there is still a relatively large delta between the current share price and our target, which is now also largely attributable to the low number of shares outstanding post-reverse split." (8/7/2019)

Has Supernus Pharmaceuticals been receiving favorable news coverage?

News stories about SUPN stock have been trending negative recently, according to InfoTrie Sentiment. The research group rates the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Supernus Pharmaceuticals earned a news sentiment score of -2.8 on InfoTrie's scale. They also gave news coverage about the specialty pharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for Supernus Pharmaceuticals.

Are investors shorting Supernus Pharmaceuticals?

Supernus Pharmaceuticals saw a increase in short interest in the month of October. As of October 15th, there was short interest totalling 6,250,000 shares, an increase of 12.0% from the September 15th total of 5,580,000 shares. Based on an average trading volume of 559,600 shares, the short-interest ratio is presently 11.2 days. Approximately 12.3% of the shares of the stock are sold short. View Supernus Pharmaceuticals' Current Options Chain.

Who are some of Supernus Pharmaceuticals' key competitors?

What other stocks do shareholders of Supernus Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Supernus Pharmaceuticals investors own include NVIDIA (NVDA), Alibaba Group (BABA), Exelixis (EXEL), Gilead Sciences (GILD), GW Pharmaceuticals PLC- (GWPH), AbbVie (ABBV), Netflix (NFLX), Baozun (BZUN), Celgene (CELG) and Pfizer (PFE).

Who are Supernus Pharmaceuticals' key executives?

Supernus Pharmaceuticals' management team includes the folowing people:
  • Mr. Jack A. Khattar, Founder, Pres, CEO, Sec. & Director (Age 58)
  • Mr. Gregory S. Patrick, Sr. VP & CFO (Age 68)
  • Dr. Padmanabh P. Bhatt, Chief Scientific Officer & Sr. VP of Intellectual Property (Age 62)
  • Dr. Stefan K. F. Schwabe, Chief Medical Officer and Exec. VP of R&D (Age 67)
  • Dr. Todd Horich M.B.A., Ph.D., VP of Marketing

Who are Supernus Pharmaceuticals' major shareholders?

Supernus Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include Rice Hall James & Associates LLC (1.79%), Scout Investments Inc. (0.98%), Carillon Tower Advisers Inc. (0.65%), Stephens Investment Management Group LLC (0.55%), Capital Management Corp VA (0.44%) and Russell Investments Group Ltd. (0.35%). Company insiders that own Supernus Pharmaceuticals stock include Gregory S Patrick, Jack A Khattar, Padmanabh P Bhatt, Stefan KF Schwabe and Victor Vaughn. View Institutional Ownership Trends for Supernus Pharmaceuticals.

Which institutional investors are selling Supernus Pharmaceuticals stock?

SUPN stock was sold by a variety of institutional investors in the last quarter, including Rice Hall James & Associates LLC, Scout Investments Inc., Carillon Tower Advisers Inc., Russell Investments Group Ltd., Chicago Equity Partners LLC, Icon Advisers Inc. Co., Stephens Investment Management Group LLC and Systematic Financial Management LP. View Insider Buying and Selling for Supernus Pharmaceuticals.

Which institutional investors are buying Supernus Pharmaceuticals stock?

SUPN stock was bought by a variety of institutional investors in the last quarter, including State of New Jersey Common Pension Fund D, Capital Management Corp VA, First Quadrant L P CA, California Public Employees Retirement System, Boston Advisors LLC, State of Alaska Department of Revenue, Bridge City Capital LLC and Virginia Retirement Systems ET AL. View Insider Buying and Selling for Supernus Pharmaceuticals.

How do I buy shares of Supernus Pharmaceuticals?

Shares of SUPN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Supernus Pharmaceuticals' stock price today?

One share of SUPN stock can currently be purchased for approximately $22.08.

How big of a company is Supernus Pharmaceuticals?

Supernus Pharmaceuticals has a market capitalization of $1.16 billion and generates $408.90 million in revenue each year. The specialty pharmaceutical company earns $110.99 million in net income (profit) each year or $2.05 on an earnings per share basis. Supernus Pharmaceuticals employs 448 workers across the globe.View Additional Information About Supernus Pharmaceuticals.

What is Supernus Pharmaceuticals' official website?

The official website for Supernus Pharmaceuticals is http://www.supernus.com/.

How can I contact Supernus Pharmaceuticals?

Supernus Pharmaceuticals' mailing address is 1550 E GUDE DR, ROCKVILLE MD, 20850. The specialty pharmaceutical company can be reached via phone at 301-838-2500 or via email at [email protected]


MarketBeat Community Rating for Supernus Pharmaceuticals (NASDAQ SUPN)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  423 (Vote Outperform)
Underperform Votes:  252 (Vote Underperform)
Total Votes:  675
MarketBeat's community ratings are surveys of what our community members think about Supernus Pharmaceuticals and other stocks. Vote "Outperform" if you believe SUPN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SUPN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/17/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel